| dc.creator |
Skiles, Jodi L. |
|
| dc.creator |
Chiang, ChienWei |
|
| dc.creator |
Li, Claire H. |
|
| dc.creator |
Martin, Steve |
|
| dc.creator |
Smith, Ellen L. |
|
| dc.creator |
Olbara, Gilbert |
|
| dc.creator |
Jones, David R. |
|
| dc.creator |
Vik, Terry A. |
|
| dc.creator |
Mostert, Saskia |
|
| dc.creator |
Abbink, Floor |
|
| dc.creator |
Kaspers, Gertjan J. |
|
| dc.creator |
Li, Lang |
|
| dc.creator |
Njuguna, Festus |
|
| dc.creator |
Sajdyk, Tammy J. |
|
| dc.creator |
Renbarger, Jamie L. |
|
| dc.date |
2018-02-05T16:34:41Z |
|
| dc.date |
2019-05-13T14:45:24Z |
|
| dc.date |
2018-03 |
|
| dc.date.accessioned |
2022-05-19T13:29:35Z |
|
| dc.date.available |
2022-05-19T13:29:35Z |
|
| dc.identifier |
Skiles, Jodi L.; Chiang, ChienWei; Li, Claire H.; Martin, Steve; Smith, Ellen L.; Olbara, Gilbert; Jones, David R.; Vik, Terry A.; Mostert, Saskia; Abbink, Floor; Kaspers, Gertjan J.; Li, Lang; Njuguna, Festus; Sajdyk, Tammy J.; Renbarger, Jamie L. (2018). "CYP3A5 genotype and its impact on vincristine pharmacokinetics and development of neuropathy in Kenyan children with cancer." Pediatric Blood & Cancer 65(3): n/a-n/a. |
|
| dc.identifier |
1545-5009 |
|
| dc.identifier |
1545-5017 |
|
| dc.identifier |
http://hdl.handle.net/2027.42/141496 |
|
| dc.identifier |
10.1002/pbc.26854 |
|
| dc.identifier |
Pediatric Blood & Cancer |
|
| dc.identifier |
Lavoie Smith EM, Cohen JA, Pett MA, Beck SL. The validity of neuropathy and neuropathic pain measures in patients with cancer receiving taxanes and platinums. Oncol Nurs Forum. 2011; 38 ( 2 ): 133 – 142. |
|
| dc.identifier |
Grisold W, Cavaletti G, Windebank AJ. Peripheral neuropathies from chemotherapeutics and targeted agents: diagnosis, treatment, and prevention. Neuro Oncol. 2012; 14 ( Suppl 4 ): iv45 – iv54. |
|
| dc.identifier |
McCune JS, Lindley C. Appropriateness of maximum‐dose guidelines for vincristine. Am J Health Syst Pharm. 1997; 54 ( 15 ): 1755 – 1758. |
|
| dc.identifier |
Dennison JB, Jones DR, Renbarger JL, Hall SD. Effect of CYP3A5 expression on vincristine metabolism with human liver microsomes. J Pharmacol Exp Ther. 2007; 321 ( 2 ): 553 – 563. |
|
| dc.identifier |
Egbelakin A, Ferguson MJ, MacGill EA, et al. Increased risk of vincristine neurotoxicity associated with low CYP3A5 expression genotype in children with acute lymphoblastic leukemia. Pediatr Blood Cancer. 2011; 56 ( 3 ): 361 – 367. |
|
| dc.identifier |
Mostert S, Arora RS, Arreola M, et al. Abandonment of treatment for childhood cancer: position statement of a SIOP PODC Working Group. Lancet Oncol. 2011; 12 ( 8 ): 719 – 720. |
|
| dc.identifier |
Eap CB, Buclin T, Hustert E, et al. Pharmacokinetics of midazolam in CYP3A4‐ and CYP3A5‐genotyped subjects. Eur J Clin Pharmacol. 2004; 60 ( 4 ): 231 – 236. |
|
| dc.identifier |
Smith EM, Beck SL, Cohen J. The Total Neuropathy Score: a tool for measuring chemotherapy‐induced peripheral neuropathy. Oncol Nurs Forum. 2008; 35 ( 1 ): 96 – 102. |
|
| dc.identifier |
Smith EM, Li L, Hutchinson RJ, et al. Measuring vincristine‐induced peripheral neuropathy in children with acute lymphoblastic leukemia. Cancer Nurs. 2013; 36 ( 5 ): E49 – 60. |
|
| dc.identifier |
Mostert S, Njuguna F, Kemps L, et al. Epidemiology of diagnosed childhood cancer in Western Kenya. Arch Dis Child. 2012; 97 ( 6 ): 508 – 512. |
|
| dc.identifier |
Strother RM, Busakhala NB, Njiru E, et al. The evolution of comprehensive cancer care in Western Kenya. J Cancer Policy. 2013; 1 ( 1–2 ): e25 – e30. |
|
| dc.identifier |
Gilchrist LS, Tanner L. The pediatric‐modified Total Neuropathy Score: a reliable and valid measure of chemotherapy‐induced peripheral neuropathy in children with non‐CNS cancers. Support Care Cancer. 2013; 21 ( 3 ): 847 – 856. |
|
| dc.identifier |
Renbarger JL, McCammack KC, Rouse CE, Hall SD. Effect of race on vincristine‐associated neurotoxicity in pediatric acute lymphoblastic leukemia patients. Pediatr Blood Cancer. 2008; 50 ( 4 ): 769 – 771. |
|
| dc.identifier |
Cavaletti G, Bogliun G, Marzorati L, et al. Grading of chemotherapy‐induced peripheral neurotoxicity using the total neuropathy scale. Neurology. 2003; 61 ( 9 ): 1297 – 1300. |
|
| dc.identifier |
Cavaletti G, Frigeni B, Lanzani F, et al. Chemotherapy‐induced peripheral neurotoxicity assessment: a critical revision of the currently available tools. Eur J Cancer. 2010; 46 ( 3 ): 479 – 494. |
|
| dc.identifier |
Cavaletti G, Frigeni B, Lanzani F, et al. The Total Neuropathy Score as an assessment tool for grading the course of chemotherapy‐induced peripheral neurotoxicity: comparison with the National Cancer Institute‐Common Toxicity Scale. J Peripher Nerv Syst. 2007; 12 ( 3 ): 210 – 215. |
|
| dc.identifier |
Cornblath DR, Chaudhry V, Carter K, et al. Total Neuropathy Score: validation and reliability study. Neurology. 1999; 53 ( 8 ): 1660 – 1664. |
|
| dc.identifier |
Gilchrist LS. Measuring chemotherapy‐induced peripheral neuropathy in children: development of the ped‐mTNS and pilot study results. Rehabil Oncol. 2009; 27 ( 3 ): 7 – 15. |
|
| dc.identifier |
Griffith KA, Merkies IS, Hill EE, Cornblath DR. Measures of chemotherapy‐induced peripheral neuropathy: a systematic review of psychometric properties. J Peripher Nerv Syst. 2010; 15 ( 4 ): 314 – 325. |
|
| dc.identifier |
Smith EM, Cohen JA, Pett MA, Beck SL. The reliability and validity of a modified Total Neuropathy Score‐reduced and neuropathic pain severity items when used to measure chemotherapy‐induced peripheral neuropathy in patients receiving taxanes and platinums. Cancer Nurs. 2010; 33 ( 3 ): 173 – 183. |
|
| dc.identifier |
Guilhaumou R, Simon N, Quaranta S, et al. Population pharmacokinetics and pharmacogenetics of vincristine in paediatric patients treated for solid tumour diseases. Cancer Chemother Pharmacol. 2011; 68 ( 5 ): 1191 – 1198. |
|
| dc.identifier |
Hartman A, van Schaik RH, van der Heiden IP, et al. Polymorphisms in genes involved in vincristine pharmacokinetics or pharmacodynamics are not related to impaired motor performance in children with leukemia. Leuk Res. 2010; 34 ( 2 ): 154 – 159. |
|
| dc.identifier |
Diouf B, Crews KR, Lew G, et al. Association of an inherited genetic variant with vincristine‐related peripheral neuropathy in children with acute lymphoblastic leukemia. JAMA. 2015; 313 ( 8 ): 815 – 823. |
|
| dc.identifier |
Lonnerholm G, Frost BM, Abrahamsson J, et al. Vincristine pharmacokinetics is related to clinical outcome in children with standard risk acute lymphoblastic leukemia. Br J Haematol. 2008; 142 ( 4 ): 616 – 621. |
|
| dc.identifier |
Howard SC, Pedrosa M, Lins M, et al. Establishment of a pediatric oncology program and outcomes of childhood acute lymphoblastic leukemia in a resource‐poor area. JAMA. 2004; 291 ( 20 ): 2471 – 2475. |
|
| dc.identifier |
Lemerle J. Management of cancer in children in Africa. Arch Pediatr. 2003; 10 ( Suppl 1 ): 247s – 249s. |
|
| dc.identifier |
Usmani GN. Pediatric oncology in the third world. Curr Opin Pediatr. 2001; 13 ( 1 ): 1 – 9. |
|
| dc.identifier |
Howard SC, Ribeiro RC, Pui CH. Strategies to improve outcomes of children with cancer in low‐income countries. Eur J Cancer. 2005; 41 ( 11 ): 1584 – 1587. |
|
| dc.identifier |
Hesseling P, Israels T, Harif M, Chantada G, Molyneux E. Practical recommendations for the management of children with endemic Burkitt lymphoma (BL) in a resource limited setting. Pediatr Blood Cancer. 2013; 60 ( 3 ): 357 – 362. |
|
| dc.identifier |
Israels T, van de Wetering MD, Hesseling P, van Geloven N, Caron HN, Molyneux EM. Malnutrition and neutropenia in children treated for Burkitt lymphoma in Malawi. Pediatr Blood Cancer. 2009; 53 ( 1 ): 47 – 52. |
|
| dc.identifier |
Chaudhry V, Rowinsky EK, Sartorius SE, Donehower RC, Cornblath DR. Peripheral neuropathy from taxol and cisplatin combination therapy: clinical and electrophysiological studies. Ann Neurol Mar. 1994; 35 ( 3 ): 304 – 11. |
|
| dc.identifier.uri |
http://localhost:8080/xmlui/handle/CUHPOERS/117270 |
|
| dc.description |
BackgroundVincristine (VCR) is a critical part of treatment in pediatric malignancies and is associated with dose‐dependent peripheral neuropathy (vincristine‐induced peripheral neuropathy [VIPN]). Our previous findings show VCR metabolism is regulated by the CYP3A5 gene. Individuals who are low CYP3A5 expressers metabolize VCR slower and experience more severe VIPN as compared to high expressers. Preliminary observations suggest that Caucasians experience more severe VIPN as compared to nonCaucasians.ProcedureKenyan children with cancer who were undergoing treatment including VCR were recruited for a prospective cohort study. Patients received IV VCR 2 mg/m2/dose with a maximum dose of 2.5 mg as part of standard treatment protocols. VCR pharmacokinetics (PK) sampling was collected via dried blood spot cards and genotyping was conducted for common functional variants in CYP3A5, multi‐drug resistance 1 (MDR1), and microtubule‐associated protein tau (MAPT). VIPN was assessed using five neuropathy tools.ResultsThe majority of subjects (91%) were CYP3A5 high‐expresser genotype. CYP3A5 low‐expresser genotype subjects had a significantly higher dose and body surface area normalized area under the curve than CYP3A5 high‐expresser genotype subjects (0.28 ± 0.15 hr·m2/l vs. 0.15 ± 0.011 hr·m2/l, P = 0.027). Regardless of which assessment tool was utilized, minimal neuropathy was detected in this cohort. There was no difference in the presence or severity of neuropathy assessed between CYP3A5 high‐ and low‐expresser genotype groups.ConclusionGenetic factors are associated with VCR PK. Due to the minimal neuropathy observed in this cohort, there was no demonstrable association between genetic factors or VCR PK with development of VIPN. Further studies are needed to determine the role of genetic factors in optimizing dosing of VCR for maximal benefit. |
|
| dc.description |
Peer Reviewed |
|
| dc.description |
https://deepblue.lib.umich.edu/bitstream/2027.42/141496/1/pbc26854_am.pdf |
|
| dc.description |
https://deepblue.lib.umich.edu/bitstream/2027.42/141496/2/pbc26854.pdf |
|
| dc.format |
application/pdf |
|
| dc.format |
application/pdf |
|
| dc.publisher |
Wiley Periodicals, Inc. |
|
| dc.rights |
IndexNoFollow |
|
| dc.subject |
vincristine |
|
| dc.subject |
cancer |
|
| dc.subject |
genotyping |
|
| dc.subject |
neuropathy |
|
| dc.subject |
pediatrics |
|
| dc.subject |
Pediatrics |
|
| dc.subject |
Health Sciences |
|
| dc.title |
CYP3A5 genotype and its impact on vincristine pharmacokinetics and development of neuropathy in Kenyan children with cancer |
|
| dc.type |
Article |
|